VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

HSPPC-96
Vaccine Information
  • Vaccine Name: HSPPC-96
  • Target Pathogen: Cancer
  • Target Disease: Cancer
  • Vaccine Ontology ID: VO_0007616
  • Type: Peptide
  • Status: Research
  • Immunization Route: Intramuscular injection (i.m.)
  • Description: Autologous tumor-derived heat shock protein-peptide complex 96 (HSPPC-96) (Eton et al., 2010).
Host Response

Human Response

  • Vaccine Immune Response Type: VO_0003057
  • Immune Response: IFNgamma-producing cell count rose modestly in 5 of 26 patients and returned to baseline by week 8, with no discernible association with HSPPC-96 dosing or clinical parameters (Eton et al., 2010).
References
Eton et al., 2010: Eton O, Ross MI, East MJ, Mansfield PF, Papadopoulos N, Ellerhorst JA, Bedikian AY, Lee JE. Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma. Journal of translational medicine. 2010; 8; 9. [PubMed: 20109236].